ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Massive rollback coming

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Aug 18, 2021 10:02am

162 Views

Post# 33722817

Massive rollback coming

Elliott and Gene orchestrated the worst deal in the companies history and will now initiate a massive 10 to 1 rollback. This does not effect them as their options are huge and their free shares and cash are more then they could have dreamed to screw you all.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property